Hepatitis B and D

Sleisenger and Fordtran’s Gastrointestinal and Liver Disease- 2 Volume Set: Pathophysiology, Diagnosis, Management, Expert Consult Premium Edition - Enhanced Online Features and Print

Volumn , Issue , 2010, Pages 1287-1312

  Perrillo, Robert ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84869137948     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-6189-2.00078-0     Document Type: Chapter

References (236)

1. Buster EH., Flink HJ., Cakaloglu Y., et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon a-2b Gastroenterology 135 2008 459-467(Ref 130.)
2. Chen CJ., Yang HI., Su J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level JAMA 295 2006 65-73(Ref 57.)
3. Doo E., Liang TJ Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection Gastroenterology 120 2001 1000-1008(Ref 34.)
4. Farci P., Chessa L., Balistrieri C., et al. Treatment of chronic hepatitis D J Viral Hepatitis 14 Suppl 1 2007 58-63(Ref 217.)
5. Fattovich G., Bortolotti F., Donato F Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors J Hepatol 48 2008 335-352(Ref 17.)
6. Hoofnagle JH., Doo E., Liang TJ., et al. Management of hepatitis B: Summary of a clinical research workshop Hepatology 45 2007 1056-1075(Ref 174.)
7. Iloeje UH., Yang HI., Su J., et al. Predicting liver cirrhosis risk based on the level of circulating hepatitis B viral load Gastroenterology 130 2006 678-686(Ref 56.)
8. Keeffe EB., Dieterich DT., Han SH., et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 Update Clin Gastroenterol Hepatol 6 2008 1315-1341(Ref 123.)
9. Keeffe EB., Zeuzem S., Koff RS., et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B Clin Gastroenterol Hepatol 5 2007 890-897(Ref 169.)
10. Lai CL., Yuen MF The natural history and treatment of chronic hepatitis B: A critical evaluation of standard treatment criteria and end points Ann Intern Med 147 2007 58-61(Ref 60.)
11. Lau GK., Piratvisuth T., Luo KX., et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B N Engl J Med 352 2005 2682-2695(Ref 127.)
12. Liaw YF., Sung JJ., Chow WC., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease N Engl J Med 351 2004 1521-1531(Ref 61.)
13. Lok AS., Lai CL., Leung N., et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B Gastroenterology 125 2003 1714-1722(Ref 35.)
14. Lok AS., McMahon BJ AASLD Practice Guidelines. Chronic hepatitis B Hepatology 45 2007 507-539(Ref 120.)
15. Marcellin P., Lau GK., Bonino F., et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B N Engl J Med 351 2004 1206-1217(Ref 128.)
16. Perrillo RP Acute flares in chronic hepatitis B. The natural and unnatural history of an immunologically mediated liver disease Gastroenterology 120 2001 1009-1022(Ref 78.)
17. Zoulim F., Perrillo R Hepatitis B: Reflections on the current approach to antiviral therapy J Hepatol 48 2008 S2-19(Ref 168.)
18. Chang MH., Chen CJ., Lai MS., et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group N Engl J Med 336 1997 1855-1859.
19. Gust ID Epidemiology of hepatitis B infection in the Western Pacific and South East Asia Gut 38 Suppl 2 1996 S18-S23.
20. Shepard CW., Simard EP., Finelli L., et al. Hepatitis B virus infection: Epidemiology and vaccination Epidemiol Rev 28 2006 112-125.
21. Lee WM Hepatitis B virus infection N Engl J Med 337 1997 1733-1745.
22. Dickson RC., Everhart JE., Lake JR., et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database Gastroenterology 113 1997 1668-1674.
23. Grob P., Jilg W., Bornhak H., et al. Serological pattern “anti-HBc alone”: Report of a workshop J Med Virol 62 2000 450-455.
24. Mason A., Wick M., White H., et al. Hepatitis B virus replication in diverse cell types during chronic hepatitis B virus infection Hepatology 18 1993 781-789.
25. Mason A., Yoffe B., Noonan C., et al. Hepatitis B virus DNA in peripheral-blood mononuclear cells in chronic hepatitis B after HBsAg clearance Hepatology 16 1992 36-41.
26. Kuhns M., McNamara A., Mason A., et al. Serum and liver hepatitis B virus DNA in chronic hepatitis B after sustained loss of surface antigen Gastroenterology 103 1992 1649-1656.
27. Fong TL., Bunnapradist S., Jordan SC., et al. Impact of hepatitis B core antibody status on outcomes of cadaveric renal transplantation: Analysis of United Network of Organ Sharing database between 1994 and 1999 Transplantation 73 2002 85-89.
28. Centers for Disease Control and Prevention A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States Morb Mortal Wkly Rep 54 RRI6 2005 1-23.
29. Alter MJ Epidemiology and prevention of hepatitis B Semin Liver Dis 23 2003 39.
30. McQuillan GM., Coleman PJ., Kruszon-Moran D., et al. Prevalence of hepatitis B virus infection in the United States: The National Health and Nutrition Examination Surveys, 1976 through 1994 Am J Public Health 89 1999 14-18.
31. Lok AS., Heathcote EJ., Hoofnagle JH Management of hepatitis B: 2000-summary of workshop Gastroenterology 120 2001 1828-1853.
32. Lee WM Acute liver failure N Engl J Med 329 1993 1862-1872.
33. Schiodt FV., Atillasoy E., Shakil AO., et al. Etiology and outcome for 295 patients with acute liver failure in the United States Liver Transpl Surg 5 1999 29-34.
34. Fattovich G., Bortolotti F., Donato F Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors J Hepatol 48 2008 335-352.
35. Weissberg JI., Andres LL., Smith CI., et al. Survival in chronic hepatitis B: An analysis of 379 patients Ann Intern Med 101 1984 613-616.
36. de Jongh FE., Janssen HL., de Man RA., et al. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver Gastroenterology 103 1992 1630-1634.
37. Niederau C., Heintgen T., Lange S., et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B N Engl J Med 334 1996 1422-1427.
38. Yuen MF., Wong DKH., Sablon E., et al. HBsAg seroclearance in chronic hepatitis B in the Chinese: Virological, histological, and clinical aspects Hepatology 39 2004 1694-1701.
39. Nowak MA., Bonhoeffer S., Hill AM., et al. Viral dynamics in hepatitis B virus infection Proc Natl Acad Sci U S A 93 1996 4398-4402.
40. Bartholomeusz A., Schaefer S Hepatitis B virus genotypes: Comparison of genotyping methods Rev Med Virol 14 2004 3-16.
41. Chu CJ., Keeffe EB., Han SH., et al. Hepatitis B virus genotypes in the United States: Results of a nationwide study Gastroenterology 125 2003 444-451.
42. Chu CJ., Lok AS Clinical significance of hepatitis B virus genotypes Hepatology 35 2002 1274-1276.
43. Ghany MG., Ayola B., Villamil FG., et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis Hepatology 27 1998 213-222.
44. Locarnini S., McMillan J., Bartholomeusz A The hepatitis B virus and common mutants Semin Liver Dis 23 2003 5-20.
45. Li J., Buckwold VE., Hon MW., Ou JH Mechanism of suppression of hepatitis B virus precore RNA transcription by a frequent double mutation J Virol 73 1999 1239-1244.
46. Guo X., Jin Y., Qian G., et al. Sequential accumulation of the mutations in core promoter of hepatitis B virus is associated with the development of hepatocellular carcinoma in Qidong, China J Hepatol 49 2008 718-725.
47. Lindh M., Andersson AS., Gusdal A Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus: Large scale analysis using a new genotyping method J Infect Dis 175 1997 1285-1293.
48. Chu CJ., Keeffe EB., Han SH., et al. Prevalence of HBV precore/core promoter variants in the United States Hepatology 38 2003 619-628.
49. Bertoletti A., Sette A., Chisari FV., et al. Natural variants of cytotoxic epitopes are T-cell receptor antagonist for antiviral cytotoxic T cells Nature 369 1994 407-410.
50. Torre F., Cramp M., Owsianka A., et al. Direct evidence that naturally occurring mutations within hepatitis B core epitope alter CD-4 T-cell reactivity J Med Virol 72 2004 370-376.
51. Doo E., Liang TJ Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection Gastroenterology 120 2001 1000-1008.
52. Lok AS., Lai CL., Leung N., et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B Gastroenterology 125 2003 1714-1722.
53. Hadziyannis SJ., Tassopoulos NC., Heathcote EJ., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to five years Gastroenterology 131 2006 1743-1751.
54. Colonno RJ., Rose R., Baldick CJ., et al. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B Hepatology 44 2006 1656-1665.
55. Dienstag JL., Goldin RD., Heathcote EJ., et al. Histological outcome during long-term lamivudine therapy Gastroenterology 124 2003 105-117.
56. Liaw YF Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B Antivir Chem Chemother 12 Suppl 1 2001 67-71.
57. Mutimer D., Pillay D., Shields P., et al. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient Gut 46 2000 107-113.
58. Rehermann B Immune responses in hepatitis B virus infection Semin Liver Dis 23 2003 21-38.
59. Guidotti LG., Chisari FV Noncytolytic control of viral infections by the innate and adaptive immune response Annu Rev Immunol 19 2001 65-91.
60. Ferrari C., Missale G., Boni C., Urbani S Immunopathogenesis of hepatitis Br J Hepatol 39 Suppl 1 2003 S36-S42.
61. Curry MP., Koziel M The dynamics of the immune response in acute hepatitis B: New lessons using new techniques Hepatology 32 2000 1177-1179.
62. Bertoletti A., Ferrari C., Fiaccadori F., et al. HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen Proc Natl Acad Sci U S A 88 1991 10445-10449.
63. Milich DR., Chen MK., Hughers JL., et al. The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: A mechanism for persistence J Immunol 160 1998 2013-2021.
64. Hadziyannis SJ., Vassilopoulos D Hepatitis B e antigen-negative chronic hepatitis B Hepatology 34 2001 617-624.
65. Perrillo RP., Brunt EM Hepatic histologic and immunohistochemical changes in chronic hepatitis B after prolonged clearance of hepatitis B surface antigen Ann Intern Med 115 1991 113-115.
66. Fattovich G Natural history and prognosis of hepatitis B Semin Liver Dis 23 2003 47-58.
67. Fattovich G., Pantalena M., Zagni I., et al. Effect of hepatitis B and C virus infection on the natural history of compensated cirrhosis: A cohort study of 297 patients Am J Gastroenterol 97 2002 2886-2895.
68. McMahon BJ The natural history of chronic hepatitis B virus infection Semin Liver Dis 24 Suppl 1 2004 17-21.
69. Kim HC., Nam CM., Jee SH., et al. Normal serum aminotransferase concentration and risk of mortality from liver diseases: Prospective-cohort study BMJ 323 2004 983.
70. Lai M., Hyatt BJ., Nasser I., et al. The clinical signficance of persistently normal ALT in chronic hepatitis B infection J Hepatol 47 2007 760-767.
71. Lin CL., Liao LY., Liu CJ., et al. Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels Hepatology 45 2007 1193-1198.
72. Hui CK., Leung N., Yuen ST., et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase Hepatology 46 2007 395-401.
73. Iloeje UH., Yang HI., Su J., et al. Predicting liver cirrhosis risk based on the level of circulating hepatitis B viral load Gastroenterology 130 2006 678-686.
74. Chen CJ., Yang HI., Su J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level JAMA 295 2006 65-73.
75. Yuen MF., Yuan HJ., Wong DKH., et al. Prognsotic determinants for chronic hepatitis B in Asians: Therapeutic implications Gut 54 2005 1610-1614.
76. Perrillo R Indications for hepatitis B treatment should be relaxed In: Arroyo V., Sanchez-Fueyo A., Fernandez-Gomez J., et al. Advances in the Therapy of Liver Diseases 2007 Ars Medica Barcelona 211.
77. Lai CL., Yuen MF The natural history and treatment of chronic hepatitis B: A critical evaluation of standard treatment criteria and end points Ann Intern Med 147 2007 58-61.
78. Liaw YF., Sung JJ., Chow WC., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease N Engl J Med 351 2004 1521-1531.
79. Koff RS Risks associated with hepatitis A and B in patients with hepatitis C J Clin Gastroenterol 33 2001 20-26.
80. Tozun N., Forbes A., Anderson MG., et al. Safety of alcohol after viral hepatitis Lancet 337 1991 1079-1080.
81. Gocke DJ Extrahepatic manifestations of viral hepatitis Am J Med Sci 270 1975 49-52.
82. Krugman S., Overby LR., Mushahwar IK., et al. Viral hepatitis type B: Studies on natural history and prevention-reexamined N Engl J Med 300 1979 101-106.
83. Rehermann B., Ferrari C., Pasquinelli C., Chisari FV The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response Nat Med 2 1996 1104-1108.
84. Pyrsopoulos NT., Reddy KR Extrahepatic manifestations of chronic viral hepatitis Curr Gastroenterol Rep 3 2001 71-78.
85. Johnson RJ., Couser WG Hepatitis B infection and renal disease: Clinical, immunopathogenetic and therapeutic considerations Kidney Int 37 1990 663-676.
86. Lai KN., Li PK., Lui SF., et al. Membranous nephropathy related to hepatitis B virus in adults N Engl J Med 324 1991 1457-1463.
87. Conjeevaram HS., Hoofnagle JH., Austin HA., et al. Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alfa Gastroenterology 109 1995 540-546.
88. Shikata T., Uzawa T., Yoshiwara N., et al. Staining methods of Australia antigen in paraffin section detection of cytoplasmic inclusion bodies Jpn J Exp Med 44 1974 25-36.
89. Perrillo RP., Campbell CR., Sanders GE., et al. Spontaneous clearance and reactivation of chronic hepatitis B virus infection among male homosexuals with chronic type B hepatitis Ann Intern Med 100 1984 43-46.
90. Mels GC., Bellati G., Leandro G., et al. Fluctuations in viremia, aminotransferases and IgM antibody to hepatitis B core antigen in chronic hepatitis B patients with disease exacerbations Liver 14 1994 175-181.
91. Di Martino V., Thevenot T., Colin JF., et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B Gastroenterology 123 2002 1812-1822.
92. Liaw YF., Tsai SL Pathogenesis and clinical significance of spontaneous exacerbations and remissions in chronic hepatitis B virus infection Viral Hepatitis 3 1997 143.
93. Xunrong L., Yan AW., Liang R., et al. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy: Pathogenesis and management Rev Med Virol 11 2001 287-299.
94. Lau JY., Lai CL., Lin HJ., et al. Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients Q J Med 73 1989 911-917.
95. Perrillo RP Acute flares in chronic hepatitis B. The natural and unnatural history of an immunologically mediated liver disease Gastroenterology 120 2001 1009-1022.
96. Liang R., Lau GK., Kwong YL Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: A review of the problem J Clin Oncol 17 1999 394-398.
97. Lau GK., Liang R., Chiu EK., et al. Hepatic events after bone marrow transplantation in patients with hepatitis B infection: A case controlled study Bone Marrow Transplant 19 1997 795-799.
98. Davies SE., Portmann BC., O’Grady JG., et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis Hepatology 13 1991 150-157.
99. Lau GK., Yiu HH., Fong DY., et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy Gastroenterology 125 2003 1742-1749.
100. Flink HJ., Sprengers D., Hansen BE., et al. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon alpha-2b therapy Gut 54 2005 1604-1609.
101. Nair S., Perrillo R Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: Is sustained clearance of HBV DNA dependent on levels of pretreatment viremia? Hepatology 34 2001 1021-1026.
102. Hoofnagle JH., Di Bisceglie AM., Waggoner JG., et al. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B Gastroenterology 104 1993 1116-1121.
103. Honkoop P., de Man RA., Niesters HG., et al. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy Hepatology 32 2000 635-639.
104. Liaw YF., Chien RN., Yeh CT., et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy Hepatology 30 1999 567-572.
105. Lok AS., Lai CL., Leung N., et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B Gastroenterology 125 2003 1714-1722.
106. Perrillo RP., Regenstein FG., Peters MG., et al. Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis: A randomized, controlled trial Ann Intern Med 109 1988 95-100.
107. Krogsgaard K., Marcellin P., Trepo C., et al. Prednisolone withdrawal therapy enhances the effect of human lymphoblastoid interferon in chronic hepatitis B. INTREPED Trial Group J Hepatol 25 1996 803-813.
108. Liaw YF., Tsai SL., Chien RN., et al. Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B Hepatology 32 2000 604-609.
109. Thio CL Hepatitis B in the human immunodeficiency virus-infected patient: Epidemiology, natural history, and treatment Semin Liver Dis 23 2003 125-136.
110. Bonino F., Brunetto MR Chronic hepatitis B e antigen (HBeAg) negative, anti-HBe positive hepatitis B: An overview J Hepatol 39 Suppl 1 2003 S160-S163.
111. Lindh M., Gustavson C., Mardberg K., et al. Mutation of nucleoside 1, 762 in the core promoter region during hepatitis B e seroconversion and its relation to liver damage in hepatitis B e antigen carriers J Med Virol 55 1998 185-190.
112. Steinberg JL., Yeo W., Zhong S., et al. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: Precore/core mutations may play an important role J Med Virol 60 2000 249-255.
113. Hadziyannis SJ Hepatitis delta: An overview In: Rizzetto M., Purcell RH., Gerin JL., Verme G Viral Hepatitis and Liver Disease: Proceedings of IX Triennial International Symposium on Viral Hepatitis and Liver Disease 1997 Edizioni Minerva Medica Turin 283.
114. Liaw YF., Tsai SL., Chang JJ., et al. Displacement of hepatitis B virus by hepatitis C virus as the cause of continuing chronic hepatitis Gastroenterology 106 1994 1048-1053.
115. Hoofnagle JH., Schafer DF Serologic markers of hepatitis B virus infection Semin Liver Dis 6 1986 1-10.
116. Perrillo RP., Chau KH., Overby LR., et al. Anti-hepatitis B core immunoglobulin M in the serologic evaluation of hepatitis B virus infection and simultaneous infection with type B, delta agent, and non-A, non-B viruses Gastroenterology 85 1983 163-167.
117. Shiels MT., Taswell HF., Czaja AJ., et al. Frequency and significance of concurrent hepatitis B surface antigen and antibody in acute and chronic hepatitis B Gastroenterology 93 1987 675-680.
118. Grob P., Jilg W., Bornhak H., et al. Serological pattern “anti-HBc”: Report on a workshop J Med Virol 62 2000 450-455.
119. Weber B., Melchior W., Gehrke R., et al. Hepatitis B virus markers in anti-HBc only positive individuals J Med Virol 64 2001 312-319.
120. Jilg W., Sieger E., Zachoval R., et al. Individuals with antibodies against hepatitis B core antigen as the only serological marker for hepatitis B infection: High percentage of carriers of hepatitis B and C virus J Hepatol 23 1995 14-20.
121. Mosley JW., Stevens CE., Aach RD., et al. Donor screening for antibody to hepatitis B core antigen and hepatitis B virus infection in transfusion recipients Transfusion 35 1995 5-12.
122. Dodson SF., Issa S., Araya V., et al. Infectivity of hepatic allografts with antibodies to hepatitis B virus Transplantation 64 1997 1582-1584.
123. Paterlini P., Gerken G., Nakajima E., et al. Polymerase chain reaction to detect hepatitis B virus DNA and RNA sequences in primary liver cancers from patients negative for hepatitis B surface antigen N Engl J Med 323 1990 80-85.
124. Chu CJ., Hussain M., Lok AS Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection Hepatology 36 2002 1408-1415.
125. Perrillo RP., Schiff ER., Davis GL., et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group N Engl J Med 323 1990 295-301.
126. Gauthier J., Bourne EJ., Lutz MW., et al. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine J Infect Dis 180 1999 1757-1762.
127. Werle B., Cinquin K., Marcellin P., et al. Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy J Viral Hepat 11 2004 74-83.
128. van Nunen AB., Hansen BE., Suh DJ., et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: Relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase Gut 52 2003 420-424.
129. Lai CL., Dienstag J., Schiff E., et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B Clin Infect Dis 36 2003 687-696.
130. Hunt CM., McGill JM., Allen MI., et al. Clinical relevance of hepatitis B viral mutations Hepatology 31 2000 1037-1044.
131. Mutimer D., Pillay D., Dragon E., et al. High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation J Hepatol 30 1999 715-721.
132. Roche B., Samuel D., Gigou M., et al. De novo and apparent de novo hepatitis B virus infection after liver transplantation J Hepatol 26 1997 517-526.
133. Brechot C., Degos F., Lugassy C., et al. Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen N Engl J Med 312 1985 270-276.
134. Wright TL., Mamish D., Combs C., et al. Hepatitis B virus and apparent fulminant non-A, non hepatitis Lancet 339 1992 952-955.
135. Wong DK., Cheung AM., O’Rourke K., et al. Effect of alpha interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: A meta-analysis Ann Intern Med 119 1993 312-323.
136. Lau DT., Everhart J., Keiner DE., et al. Long-term follow up of patients with chronic hepatitis B treated with interferon alfa Gastroenterology 113 1997 1660-1667.
137. Lok AS., McMahon BJ AASLD Practice Guidelines. Chronic hepatitis B Hepatology 45 2007 507-539.
138. Liaw YF., Leung N., Guan R., et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2005 update Liver International 25 2005 472-489.
139. European Association for the Study of the Liver EASL Clinical Practice Guidelines: Management of chronic hepatitis B J Hepatol 50 2009 227-242.
140. Keeffe EB., Dieterich DT., Han SH., et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 Update Clin Gastroenterol Hepatol 6 2008 1315-1341.
141. Perrillo RP., Lai CL., Liaw YF., et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B Hepatology 36 2002 186-194.
142. Cooksley WG Treatment with interferons in patients with hepatitis B Semin Liver Dis 24 Suppl 1 2004 45-53.
143. Janssen HL., van Zonneveld M., Senturk H., et al. Pegylated interferon alfa-2b, alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomized trial Lancet 365 2005 123-129.
144. Lau GK., Piratvisuth T., Luo KX., et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B N Engl J Med 352 2005 2682-2695.
145. Marcellin P., Lau GK., Bonino F., et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B N Engl J Med 351 2004 1206-1217.
146. Kao JH., Wu NH., Chen PJ., et al. Hepatitis B genotypes and the response to interferon therapy J Hepatol 33 2000 998-1002.
147. Buster EH., Flink HJ., Cakaloglu Y., et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon a-2b Gastroenterology 135 2008 459-467.
148. Erhardt A., Ludwig AD., Brunetto M., et al. HBV genotypes are the strongest predictors of response to interferon-alfa treatment: Multivariate evaluation in 1229 hepatitis B patients [abstract] Hepatology 48 2008 700A.
149. Lai CL., Chien RN., Leung NW., et al. A one-year trial of lamivudine for chronic hepatitis Engl J Med 339 1998 61-68.
150. Dienstag JL., Schiff ER., Wright TL., et al. Lamivudine as initial treatment for chronic hepatitis B in the United States N Engl J Med 341 1999 1256-1263.
151. Liaw YF., Leung NW., Chang TT., et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B Gastroenterology 119 2000 172-180.
152. Marcellin P., Chang TT., Lim SG., et al. Adefovir dipivoxil for the treatment of hepatitis antigen-positive chronic hepatitis B N Engl J Med 348 2003 808-816.
153. Hadziyannis SJ., Tassopoulos NC., Heathcote EJ., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B N Engl J Med 348 2003 800-807.
154. Marcellin P, Chang T, Lim S, et al. Adefovir dipivoxil (ADV) 10 mg for the treatment of patients with HBeAg+ chronic hepatitis B: Continued efficacy beyond 48 weeks [Abstract 840]. In: Programs and Abstracts from the 53rd Annual Meeting of the American Association for the Study of Liver, November 1-5, 2002, Boston.
155. Westland C., Delaney W 4th., Yang H., et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil Gastroenterology 125 2003 107-116.
156. Angus P., Vaughan R., Xiong S., et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase Gastroenterology 125 2003 292-297.
157. Hadziyannis S., Tassopoulos N., Heathcote EJ., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B N Engl J Med 352 2005 2673-2681.
158. Locarnini S., Qi X., Arterburn S., et al. Incidence and predictors of emergence of adefovir resistant HBV during 4 years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B [abstract] J Hepatol 42 2005 17.
159. Marcellin P., Chang TT., Lim SG., et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B Hepatology 48 2008 750-758.
160. Hadziyannis SJ., Tassopoulos NC., Heathcote EJ., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years Gastroenterology 131 2006 1743-1751.
161. Yang H, Westland CE, Das K, et al. In vitro characterization and molecular modeling analysis of adefovir resistance mutation rtN236T in the HBV polymerase [Abstract 054]. In: Programs and Abstracts from the Hep Dart Meeting, December 14-8, 2003, Kauai, Hawaii.
162. Perrillo R., Hann HW., Mutimer D., et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus Gastroenterology 126 2004 81-90.
163. Schiff ER., Lai CL., Hadziyannis S., et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre-and post-liver transplantation patients Hepatology 38 2003 1419-1427.
164. Fung SK., Chae HB., Fontana RJ., et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B J Hepatol 44 2006 283-290.
165. Lampertico P., Vigano M., Manenti E., et al. Low resistance to adefovir combined with lamivudine: A 3 year study of 145 lamivudine-resistant hepatitis B patients Gastroenterology 133 2007 1445-1451.
166. Lampertico P., Vigano M., Manenti E., et al. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine Hepatology 42 2005 1414-1419.
167. Chang TT., Gish RG., de Man R., et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B N Engl J Med 354 2006 1001-1010.
168. Lai CL., Shouval D., Lok AS., et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B N Engl J Med 354 2006 1011-1020.
169. Gish RG., Lok AS., Chang TT., et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B Gastroenterology 133 2007 1437-1444.
170. Tenney DJ., Rose RE., Baldick CJ., et al. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present Antimicrob Agents Chemother 51 2007 902-911.
171. Lai CL., Leung N., Teo EK., et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B Gastroenterology 129 2005 528-536.
172. Lai CL., Gane E., Liaw YF., et al. Telbivudine versus lamivudine in patients with chronic hepatitis B N Engl J Med 357 2007 2576-2588.
173. Liaw YF., Gane E., Leung N., et al. 2-year GLOBE trial results: Telbivudine is superior to lamivudine in patients with chronic hepatitis B Gastroenterology 136 2009 486-495.
174. Heathcote EJ., Gane EJ., deMan RA Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-positive patients with chronic hepatitis B (study 103), preliminary analysis [abstract] Hepatology 48 2008 376A.
175. Marcellin P., Heathcote EJ., Buti M., et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B N Engl J Med 359 2008 2442-2455.
176. Van Bommel F., Trojan J., Feucht HH., et al. Tenofovir shows limited efficacy in treatment of HBV infections resistant against adefovir [abstract] Hepatology 46 2007 664A.
177. Parsonage MJ., Wilkins EG., Snowden N., et al. The development of hypophosphatemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy HIV Med 6 2005 341-346.
178. Winston J., Deray G., Hawkins T., et al. Kidney disease in patients with HIV infection and AIDS Clin Infect Dis 47 2008 1449-1457.
179. Gupta SK Tenofovir-associated Fanconi syndrome: Review of the FDA adverse event reporting system AIDS Patient Care STDS 22 2008 99-103.
180. Raffi F, Snow A, Borroto-Esoda K, et al. Anti-HBV activity of emtricitabine (FTC) in patients co-infected with HIV and hepatitis B virus [Abstract 215]. In: Programs and Abstracts of the 2nd IAS Conference on Pathogenesis and Treatment, July 13-16, 2003, Paris.
181. Gish R., Leung N., Wang C., et al. Antiviral activity, safety, and incidence of resistance in chronically infected hepatitis B patients (CHB) given once daily emtricitabine for 2 years [abstract] Hepatology 36 2003 372A.
182. Lee HS, Chung YH, Lee KS, et al. A 12-week randomized placebo controlled double blind trial of clevudine in patients with chronic hepatitis B with post-treatment follow up for 24 weeks [Abstract 052]. In: Programs and Abstracts from the Hep Dart Meeting, December 14-18, 2003, Kauai, Hawaii.
183. Marcellin P., Mommeja-Marin H., Sacks SL., et al. A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B Hepatology 40 2004 140-148.
184. Yoo BC., Kim JH., Kim TH., et al. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression Hepatology 46 2007 1041-1048.
185. Zoulim F., Perrillo R., Hepatitis B Reflections on the current approach to antiviral therapy J Hepatol 48 2008 S2-19.
186. Keeffe EB., Zeuzem S., Koff RS., et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B Clin Gastroenterol Hepatol 5 2007 890-897.
187. Yim HJ., Hussain M., Liu Y., et al. Evolution of multi-drug resistant hepatitis B virus during sequential therapy Hepatology 44 2006 703-712.
188. Sung JJ., Lai JY., Zeuzem S., et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B J Hepatol 48 2008 728-735.
189. Su GG., Pan KH., Zhao KF., et al. Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy World J Gastroenterol 10 2004 910-912.
190. van Zonneveld M., van Nunen AB., Niesters HG., et al. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection J Viral Hepat 10 2003 294-297.
191. Hoofnagle JH., Doo E., Liang TJ., et al. Management of hepatitis B: Summary of a clinical research workshop Hepatology 45 2007 1056-1075.
192. Perrillo R., Tamburro C., Regenstein F., et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus Gastroenterology 109 1995 908-916.
193. Buster EH., Hansen BE., Buti M., et al. Peginterferon alfa-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis Hepatology 46 2007 388-394.
194. Chu CM., Liaw YF Hepatitis B virus-related cirrhosis: Natural history and treatment Semin Liv Dis 26 2006 142-152.
195. Bica I., McGovern B., Dhar R., et al. Increasing mortality due to end-stage liver disease in patients with HIV infection Clin Infect Dis 32 2001 492-497.
196. Thio CL., Locarnini S Treatment of HIV/HBV coinfection: Clinical and virologic issues AIDS Rev 9 2007 40-53.
197. McMahon MA., Jilek BL., Brennan TP., et al. The HBV drug entecavir-effects on HIV-1 replication and resistance N Engl J Med 356 2007 2614-2621.
198. Chu CJ., Lee SD Hepatitis B virus/hepatitis C virus coinfection: Epidemiology, clinical features, viral interactions and treatment J Gastroenterol Hepatol 23 2008 512-520.
199. Potthoff A., Wedemeyer H., Boecher WO., et al. The HEP-NET B/C coinfection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon alfa-2b and ribavirin in patients with HBV/HCV coinfection J Hepatol 49 2008 688-694.
200. Bocher WO., Herzog-Hauff S., Herr W., et al. Regulation of the neutralizing anti-hepatitis B surface (HBs) antibody response in vitro in HBs vaccine recipients and patients with acute chronic hepatitis B virus (HBV) infection Clin Exp Immunol 105 1996 52-58.
201. Szmuness W., Stevens CE., Harley EJ., et al. Hepatitis B vaccine: Demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States N Engl J Med 303 1980 833-841.
202. Hadler SC., Francis DP., Maynard JE., et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men N Engl J Med 315 1986 209-214.
203. Seaworth B., Drucker J., Starling J., et al. Hepatitis B vaccines in patients with chronic renal failure before dialysis J Infect Dis 157 1988 332-337.
204. Wilson CC., Olson WC., Tuting T., et al. HIV-1 specific CTL responses primed in vitro by blood derived dendritic cells and Th1-biasing cytokines J Immunol 162 1999 3070-3078.
205. Rahman F., Dahmen A., Herzog-Hauff S., et al. Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen Hepatology 31 2000 521-527.
206. Hepatitis B virus: A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP) MMWR Recomm Rep 40 RR-13 1991 1-25.
207. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection MMWR Recomm Rep 57 RR-08 2008 1-20.
208. Lopez P., Rubiano L., del Pilar Rubio M., et al. Immunogenicity and reactogenicity of DTPw-HB/Hib vaccine administered to Colombian infants after a birth dose of hepatitis B vaccine Expert Rev Vaccines 1 2002 277-283.
209. Murdoch DL., Goa K., Figgitt DP Combined hepatitis A and B vaccines: A review of their immunogenicity and tolerability Drugs 63 2003 2625-2649.
210. Rizzetto M., Canese MG., Arico S., et al. Immunofluorescence detection of a new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers Gut 18 1977 997-1003.
211. Nath N., Mushawar IK., Fang CT., et al. Antibodies to delta antigen in asymptomatic hepatitis B surface antigen-reactive blood donors in the United States and their association with other markers of hepatitis B virus Am J Epidemiol 122 1985 218-225.
212. Gaeta GB., Stroffolini T., Chiaramonte M., et al. Chronic hepatitis D: A vanishing disease? An Italian multicenter study Hepatology 32 2000 824-827.
213. Sagnelli E., Stroffolini T., Ascione A., et al. Decrease in HDV endemicity in Italy J Hepatol 26 1997 20-24.
214. Navascues CA., Rodriguez M., Sotorrio NG., et al. Epidemiology of hepatitis D virus infection: Changes in the last 14 years Am J Gastroenterol 90 1995 1981-1984.
215. Coppola RC., Manconi PE., Piro R., et al. HCV, HIV HBV, and HDV infection in drug addicts Eur J Epidemiol 10 1994 279-283.
216. Shakil AO., Hadziyannis S., Hoofnagle JH., et al. Geographic distribution and genetic variability of hepatitis delta virus genotype I Virology 234 1997 160-167.
217. Zhang YY., Tsega E., Hansson BG Phylogenetic analysis of hepatitis D viruses indicating a new genotype I subgroup among African isolates J Clin Microbiol 34 1996 3023-3030.
218. Lee CM., Changchien CS., Chung JC., et al. Characterization of a new genotype II hepatitis delta virus from Taiwan J Med Virol 49 1996 145-154.
219. Casey JL., Niro GA., Engle RE., et al. Hepatitis B virus (HBV)/hepatitis D virus (HDV) coinfection in outbreaks of acute hepatitis in the Peruvian Amazon Basin: The roles of HDV genotype III and HBV genotype F J Infect Dis 174 1996 920-926.
220. Wang KS., Choo QL., Weiner AJ., et al. Structure, sequence and expression of hepatitis delta (delta) viral genome Nature 323 1986 508-514.
221. Taylor JM The structure and replication of hepatitis delta virus Annu Rev Microbiol 46 1992 253-276.
222. Luo GX., Chao M., Hsieh SY., et al. A specific base transition occurs on replicating hepatitis delta virus RNA J Virol 64 1989 1021-1027.
223. Chao M., Hsieh SY., Taylor J Role of two forms of hepatitis delta virus antigen: Evidence for a mechanism of self-limiting genome replication J Virol 64 1990 5066-5069.
224. Samuel D., Zignego AL., Reynes M., et al. Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis Hepatology 21 1995 333-339.
225. Tang JR., Cova L., Lamelin JP., et al. Clinical relevance of the detection of hepatitis delta virus RNA in serum by RNA hybridization and polymerase chain reaction J Hepatol 21 1994 953-960.
226. Borghesio B., Rosina F., Smedile A., et al. Serum immunoglobulin M antibody to hepatitis D as a surrogate marker of hepatitis D in interferon-treated patients and in patients who underwent liver transplantation Hepatology 27 1998 873-876.
227. Huang YH., Wu JC., Sheng WY., et al. Diagnostic value of anti-hepatitis D virus (HDV) antibodies revisited: A study of total and IgM anti-HDV compared with detection of HDV-RNA by polymerase chain reaction J Gastroenterol Hepatol 13 1998 57-61.
228. Rizzetto M., Ponzetto A., Forzani I Epidemiology of hepatitis delta virus: Overview Prog Clin Biol Res 364 1991 1-20.
229. Realdi G., Fattovich G., Hadziyannis S., et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: A multicenter study. The investigators of the European Concerted Action on Viral Hepatitis (EUROHEP) J Hepatol 21 1994 656-666.
230. DiMarco V., Lo Iacono O., Camma C., et al. The long-term course of chronic hepatitis B Hepatology 30 1999 257-264.
231. Tassopoulos NC., Koutelou MG., Macagno S., et al. Diagnostic significance of IgM antibody to hepatitis delta virus in fulminant hepatitis B J Med Virol 30 1990 174-177.
232. Wu JC., Chen TZ., Huang YS., et al. Natural history of hepatitis D viral superinfection: Significance of viremia detected by polymerase chain reaction Gastroenterology 108 1995 796-802.
233. Shakil AO., Hadziyannis S., Hoofnagle JH., et al. Geographic distribution and genetic variability of hepatitis delta virus genotype I Virology 234 1997 160-167.
234. Farci P., Chessa L., Balistrieri C., et al. Treatment of chronic hepatitis D J Viral Hepatitis 14 Suppl 1 2007 58-63.
235. Carosi G., Rizzetto M Treatment of chronic hepatitis B: Recommendations from an Italian workshop Dig Liver Dis 40 2008 603-617.
236. Yurdaydin C., Bozkaya H., Onder FO., et al. Treatment of chronic delta hepatitis with lamivudine vs. lamivudine + interferon vs. interferon J Viral Hepatitis 15 2008 314-321.